Related Topics News -

     
 Detail   |   Print    Next page > 
     
荃信生物魯塞奇塔單抗注射液上市申請獲受理
2026-03-09T  
荃信生物共計回購248.78萬股 涉資5,075萬
2026-02-06T  
荃信生物QX030N/CLD-423完成I期臨床試驗首批受試者給藥
2026-01-14T  
荃信生物共計回購157.58萬股 總額3,116萬元
2026-01-07T  
荃信生物(02509.HK)授出QX027N商業化權利 可獲高達7億美元付款
2025-12-22T  
荃信生物收到Caldera里程碑付款500萬美元
2025-12-09T  
荃信生物長效雙抗QX027N獲兩項臨床試驗默示許可
2025-11-13T  
荃信生物合共回購54.98萬股 涉資1,107萬元
2025-11-11T  
荃信生物與羅氏達成全球獨家合作與許可協議
2025-10-28T  
荃信生物產業化基地通過歐盟QP審計
2025-10-12T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.